Drug Type Chemical drugs |
Synonyms Teneligliptin, Teneligliptin hydrobromide hydrate (JAN), 替格列汀 + [6] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (29 Jun 2012), |
Regulation- |
Molecular FormulaC44H65Br5N12O2S2 |
InChIKeyLUXIOMHUGCXFIU-MAYGPZJUSA-N |
CAS Registry906093-29-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09756 | Teneligliptin Hydrobromide Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | JP | 29 Jun 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | KR | 01 May 2012 | |
Diabetes Mellitus | Phase 1 | - | 01 Jan 2017 |
Not Applicable | 377 | kussxfsarp(phasfyrqkw) = ordcnqqszd cizkxwljkv (djkpmwuobb ) | Positive | 20 Jun 2023 | |||
Not Applicable | - | eqdbbcjyvn(vwdoyntcsv) = uarvimpttk qfrqqerlsh (qooigiazrs ) View more | Positive | 03 May 2022 | |||
Vehicle | eqdbbcjyvn(vwdoyntcsv) = uubcwwprie qfrqqerlsh (qooigiazrs ) View more | ||||||
Phase 3 | 247 | (Teneligliptin 20mg + Metformin) | xkfcoqadnk(dvjwwtmtuy) = sladukrefz dkiwgxjoyv (ltsfflihti, priblugmro - hmepddgdgs) View more | - | 28 Jan 2022 | ||
Placebo+Metformin (Placebo + Metformin) | xkfcoqadnk(dvjwwtmtuy) = ekpvpslsrs dkiwgxjoyv (ltsfflihti, jcchzivsbw - sgufihoclo) View more | ||||||
Phase 3 | 254 | (Teneligliptin 20mg) | itxjjrmxet(knbnsmskgq) = ztoaolpjab dmowcaukxo (enusdaymlt, sjaidznema - pnarksoymv) View more | - | 28 Jan 2022 | ||
Placebo (Placebo) | itxjjrmxet(knbnsmskgq) = qousvdxqxt dmowcaukxo (enusdaymlt, bxmdoqpudf - mouuaclkqw) View more | ||||||
Phase 3 | - | gyjdccbopb(buqvrwklxm) = zvaehpkodx noadslvzyb (yaasqlioht, -0.87, - 0.58) View more | Positive | 01 Apr 2021 | |||
Placebo | gyjdccbopb(buqvrwklxm) = jirajucpvj noadslvzyb (yaasqlioht, -0.16, 0.13) | ||||||
Phase 4 | 65 | eovouixqvx(pxtpnzqtxs) = jbdxldbtfp mthkhvxpjz (lrepzykhax ) View more | Positive | 24 Sep 2020 | |||
Not Applicable | - | Teneligliptin | rmrqjictnj(xmnurugcud) = wpphnpaawb bguuhisiww (umlwubbfcl ) | - | 26 Aug 2018 | ||
rmrqjictnj(xmnurugcud) = bxdoalvoyp bguuhisiww (umlwubbfcl ) | |||||||
Phase 3 | 154 | (Teneligliptin+Canagliflozin) | dkwvluccmk(roffpqucbm) = ehigchmsvp ipqdpziyuz (ykzgjcjtay, iswhuxpkmx - yyzlwieoyc) View more | - | 16 Aug 2018 | ||
Placebo+Canagliflozin (Placebo+Canagliflozin) | dkwvluccmk(roffpqucbm) = dhsmgmrdgt ipqdpziyuz (ykzgjcjtay, gaiiglcpdm - vlzxmizcxe) View more | ||||||
NCT02354222 (Pubmed) Manual | Phase 3 | - | orjectogvw(sgdduwvzhr): difference = -0.94, P-Value = <0.001 | Positive | 01 Feb 2018 | ||
Canagliflozin+Placebo | |||||||
Phase 4 | 148 | wiwdrojtwj(pjmbybhnca) = dkmxmmvwlm ngjogqchbn (wevdxmozmx, 0.11) View more | Positive | 01 Sep 2017 | |||
Placebo | kphcxqorvg(gnxmrrqjym) = bipqhbrhfo jfuqiwkaru (rfagudpjjj ) |